Published online Aug 28, 2020. doi: 10.13105/wjma.v8.i4.292
Peer-review started: July 29, 2020
First decision: August 22, 2020
Revised: August 28, 2020
Accepted: August 28, 2020
Article in press: August 28, 2020
Published online: August 28, 2020
Processing time: 43 Days and 8.7 Hours
Helicobacter pylori (H. pylori) is a gram-negative microaerophilic bacterium that infects the gastric epithelium and whose acquisition occurs mainly during childhood. In the last several years, no significant changes in the treatment of infected children have been observed, mainly due to the lack of studies with satisfactory scientific evidence to support the indication of new therapies in clinical practice. This systematic review evaluated the eradication rates of H. pylori infection using various therapeutic regimens and their positive and negative outcomes in pediatric patients.
Standard triple therapy for the eradication of H. pylori infection has been used as first-line treatment in children worldwide. However, the effectiveness of standard triple therapy in eradicating H. pylori is decreasing in various geographical areas as a consequence of increasing bacterial resistance to clarithromycin and nitroimidazoles.
To compare the eradication rates of H. pylori infection in childhood in controlled, randomized, and prospective studies evaluating different therapeutic schemes during the last 10 years.
We systematically reviewed in PubMed and MEDLINE relevant publications from 2010 to April 2020. Twenty studies were shortlisted. This systematic review uses guidance from the PRISMA checklist.
The results were quite heterogeneous. Standard triple therapy is still the most used regimen and its eradication rates vary according to the H. pylori susceptibility profiles in different world regions. The addition of probiotics to therapeutic schemes shows discrepant results in eradication rate, but decrease the incidence of side effects and increases the treatment adherence. Sequential therapy has been associated with higher eradication rates than triple therapies and is a promising therapeutic regimen for this population.
Currently, standard triple therapy is the most recommended H. pylori eradication regimen for children worldwide. However, other therapeutic schemes have shown promising results in controlled trials and in a near future may be included in the guidelines recommendations.
There are still few studies with satisfactory evidence levels evaluating the eradication of H. pylori infection in children, mainly due to the difficulties to conduct controlled clinical trials as well as to the low availability of sources for research in many developing countries where the prevalence of H. pylori infection remain elevated. Well-designed studies evaluating treatments for H. pylori eradication in children are needed to further evaluate new therapeutic options in pediatric clinical practice in high bacterial resistance settings.